Aurobindo Pharma Limited

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SUNPHARMA.NS has a market cap of 4.2T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SUNPHARMA.NS trades at ₹1,753.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SUNPHARMA.NS's P/E ratio is 38.65. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUNPHARMA.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SUNPHARMA.BO has a market cap of 4.2T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SUNPHARMA.BO trades at ₹1,752.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SUNPHARMA.BO's P/E ratio is 38.60. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUNPHARMA.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, DIVISLAB.NS has a market cap of 1.6T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while DIVISLAB.NS trades at ₹6,026.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas DIVISLAB.NS's P/E ratio is 64.43. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check DIVISLAB.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, DIVISLAB.BO has a market cap of 1.6T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while DIVISLAB.BO trades at ₹6,022.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas DIVISLAB.BO's P/E ratio is 64.39. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check DIVISLAB.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while TORNTPHARM.BO trades at ₹4,256.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas TORNTPHARM.BO's P/E ratio is 66.62. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check TORNTPHARM.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while TORNTPHARM.NS trades at ₹4,256.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas TORNTPHARM.NS's P/E ratio is 62.86. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check TORNTPHARM.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while LUPIN.BO trades at ₹2,331.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas LUPIN.BO's P/E ratio is 24.34. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check LUPIN.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while LUPIN.NS trades at ₹2,331.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas LUPIN.NS's P/E ratio is 22.63. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check LUPIN.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, DRREDDY.NS has a market cap of 1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while DRREDDY.NS trades at ₹1,259.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas DRREDDY.NS's P/E ratio is 18.45. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check DRREDDY.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, DRREDDY.BO has a market cap of 1T. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while DRREDDY.BO trades at ₹1,259.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas DRREDDY.BO's P/E ratio is 18.46. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check DRREDDY.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ZYDUSLIFE.NS has a market cap of 866B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ZYDUSLIFE.NS trades at ₹886.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ZYDUSLIFE.NS's P/E ratio is 17.54. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ZYDUSLIFE.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ZYDUSLIFE.BO has a market cap of 865.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ZYDUSLIFE.BO trades at ₹886.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ZYDUSLIFE.BO's P/E ratio is 17.54. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ZYDUSLIFE.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, MANKIND.NS has a market cap of 795.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while MANKIND.NS trades at ₹1,987.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas MANKIND.NS's P/E ratio is 44.62. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check MANKIND.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, MANKIND.BO has a market cap of 793.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while MANKIND.BO trades at ₹1,987.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas MANKIND.BO's P/E ratio is 44.51. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check MANKIND.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, AUROPHARMA.BO has a market cap of 743B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while AUROPHARMA.BO trades at ₹1,281.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas AUROPHARMA.BO's P/E ratio is 21.72. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AUROPHARMA.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ALKEM.BO has a market cap of 615.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ALKEM.BO trades at ₹5,298.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ALKEM.BO's P/E ratio is 25.96. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ALKEM.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ALKEM.NS has a market cap of 615.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ALKEM.NS trades at ₹5,297.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ALKEM.NS's P/E ratio is 25.95. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ALKEM.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, GLENMARK.NS has a market cap of 589.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while GLENMARK.NS trades at ₹2,095.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas GLENMARK.NS's P/E ratio is 55.38. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLENMARK.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, GLENMARK.BO has a market cap of 587.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while GLENMARK.BO trades at ₹2,096.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas GLENMARK.BO's P/E ratio is 55.16. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLENMARK.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, LAURUSLABS.BO has a market cap of 519.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while LAURUSLABS.BO trades at ₹992.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas LAURUSLABS.BO's P/E ratio is 61.68. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check LAURUSLABS.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, LAURUSLABS.NS has a market cap of 519B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while LAURUSLABS.NS trades at ₹992.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas LAURUSLABS.NS's P/E ratio is 61.63. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check LAURUSLABS.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SUVENPHAR.NS's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUVENPHAR.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUVENPHAR.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, IPCALAB.BO has a market cap of 388.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while IPCALAB.BO trades at ₹1,536.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas IPCALAB.BO's P/E ratio is 42.71. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check IPCALAB.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, IPCALAB.NS has a market cap of 388.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while IPCALAB.NS trades at ₹1,530.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas IPCALAB.NS's P/E ratio is 42.69. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check IPCALAB.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, AJANTPHARM.BO has a market cap of 349.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while AJANTPHARM.BO trades at ₹2,862.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas AJANTPHARM.BO's P/E ratio is 34.53. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AJANTPHARM.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, AJANTPHARM.NS has a market cap of 349.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while AJANTPHARM.NS trades at ₹2,863.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas AJANTPHARM.NS's P/E ratio is 34.39. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AJANTPHARM.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, JBCHEPHARM.BO has a market cap of 334.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while JBCHEPHARM.BO trades at ₹2,075.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas JBCHEPHARM.BO's P/E ratio is 43.92. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check JBCHEPHARM.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, JBCHEPHARM.NS has a market cap of 334B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while JBCHEPHARM.NS trades at ₹2,076.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas JBCHEPHARM.NS's P/E ratio is 43.81. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check JBCHEPHARM.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, EMCURE.NS has a market cap of 279B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while EMCURE.NS trades at ₹1,539.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas EMCURE.NS's P/E ratio is 32.01. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check EMCURE.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check PEL.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ASTRAZEN.BO has a market cap of 203.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ASTRAZEN.BO trades at ₹8,289.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ASTRAZEN.BO's P/E ratio is 101.24. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ASTRAZEN.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ASTRAZEN.NS has a market cap of 203.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ASTRAZEN.NS trades at ₹8,276.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ASTRAZEN.NS's P/E ratio is 101.03. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ASTRAZEN.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, WOCKPHARMA.BO has a market cap of 179B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while WOCKPHARMA.BO trades at ₹1,141.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas WOCKPHARMA.BO's P/E ratio is 853.80. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check WOCKPHARMA.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, WOCKPHARMA.NS has a market cap of 178.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while WOCKPHARMA.NS trades at ₹1,138.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas WOCKPHARMA.NS's P/E ratio is 852.95. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check WOCKPHARMA.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ERIS.BO has a market cap of 177.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ERIS.BO trades at ₹1,281.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ERIS.BO's P/E ratio is 40.59. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ERIS.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, PPLPHARMA.BO has a market cap of 176.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while PPLPHARMA.BO trades at ₹136.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas PPLPHARMA.BO's P/E ratio is -107.30. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check PPLPHARMA.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ERIS.NS has a market cap of 176.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ERIS.NS trades at ₹1,281.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ERIS.NS's P/E ratio is 40.21. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ERIS.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, NATCOPHARM.BO has a market cap of 166.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while NATCOPHARM.BO trades at ₹949.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas NATCOPHARM.BO's P/E ratio is 10.80. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NATCOPHARM.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, NATCOPHARM.NS has a market cap of 166.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while NATCOPHARM.NS trades at ₹949.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas NATCOPHARM.NS's P/E ratio is 10.67. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NATCOPHARM.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, NEULANDLAB.NS has a market cap of 148.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while NEULANDLAB.NS trades at ₹12,030.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas NEULANDLAB.NS's P/E ratio is 83.05. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NEULANDLAB.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, NEULANDLAB.BO has a market cap of 148.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while NEULANDLAB.BO trades at ₹12,030.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas NEULANDLAB.BO's P/E ratio is 82.94. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NEULANDLAB.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, GRANULES.BO has a market cap of 141.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while GRANULES.BO trades at ₹608.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas GRANULES.BO's P/E ratio is 25.86. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GRANULES.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, GRANULES.NS has a market cap of 140.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while GRANULES.NS trades at ₹606.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas GRANULES.NS's P/E ratio is 25.76. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GRANULES.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to GLS.NS's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLS.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GLS.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, JUBLPHARMA.NS has a market cap of 129.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while JUBLPHARMA.NS trades at ₹860.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas JUBLPHARMA.NS's P/E ratio is 29.93. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check JUBLPHARMA.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, JUBLPHARMA.BO has a market cap of 128.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while JUBLPHARMA.BO trades at ₹859.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas JUBLPHARMA.BO's P/E ratio is 29.93. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check JUBLPHARMA.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, APLLTD.NS has a market cap of 127.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while APLLTD.NS trades at ₹673.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas APLLTD.NS's P/E ratio is 20.18. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to APLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check APLLTD.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, APLLTD.BO has a market cap of 127B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while APLLTD.BO trades at ₹672.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas APLLTD.BO's P/E ratio is 20.14. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to APLLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check APLLTD.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, CAPLIPOINT.NS has a market cap of 118.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while CAPLIPOINT.NS trades at ₹1,586.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas CAPLIPOINT.NS's P/E ratio is 19.38. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check CAPLIPOINT.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, CAPLIPOINT.BO has a market cap of 118.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while CAPLIPOINT.BO trades at ₹1,587.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas CAPLIPOINT.BO's P/E ratio is 19.36. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check CAPLIPOINT.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, COHANCE.BO has a market cap of 115B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while COHANCE.BO trades at ₹295.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas COHANCE.BO's P/E ratio is 59.43. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check COHANCE.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, COHANCE.NS has a market cap of 114.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while COHANCE.NS trades at ₹296.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas COHANCE.NS's P/E ratio is 59.38. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check COHANCE.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ALIVUS.BO has a market cap of 114.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ALIVUS.BO trades at ₹969.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ALIVUS.BO's P/E ratio is 21.14. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ALIVUS.BO's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ALIVUS.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ALIVUS.NS has a market cap of 114.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ALIVUS.NS trades at ₹969.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ALIVUS.NS's P/E ratio is 21.11. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ALIVUS.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check CAPPL.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, STAR.NS has a market cap of 83.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while STAR.NS trades at ₹910.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas STAR.NS's P/E ratio is 16.41. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check STAR.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, STAR.BO has a market cap of 83.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while STAR.BO trades at ₹911.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas STAR.BO's P/E ratio is 16.36. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check STAR.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, PGHL.NS has a market cap of 80B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while PGHL.NS trades at ₹4,843.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas PGHL.NS's P/E ratio is 33.85. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check PGHL.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, PGHL.BO has a market cap of 79.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while PGHL.BO trades at ₹4,847.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas PGHL.BO's P/E ratio is 33.74. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check PGHL.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, VIYASH.NS has a market cap of 78.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while VIYASH.NS trades at ₹188.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas VIYASH.NS's P/E ratio is 69.72. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check VIYASH.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, AKUMS.NS has a market cap of 71.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while AKUMS.NS trades at ₹477.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas AKUMS.NS's P/E ratio is 22.39. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to AKUMS.NS's ROE of +0.11%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AKUMS.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SHILPAMED.NS has a market cap of 61.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SHILPAMED.NS trades at ₹338.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SHILPAMED.NS's P/E ratio is 27.62. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SHILPAMED.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, AARTIPHARM.NS has a market cap of 56B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while AARTIPHARM.NS trades at ₹622.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas AARTIPHARM.NS's P/E ratio is 26.25. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AARTIPHARM.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, AARTIPHARM.BO has a market cap of 55.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while AARTIPHARM.BO trades at ₹622.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas AARTIPHARM.BO's P/E ratio is 26.21. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AARTIPHARM.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, FDC.NS has a market cap of 53.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while FDC.NS trades at ₹331.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas FDC.NS's P/E ratio is 24.65. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check FDC.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, FDC.BO has a market cap of 53.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while FDC.BO trades at ₹331.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas FDC.BO's P/E ratio is 24.68. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check FDC.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SEQUENT.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SEQUENT.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, INNOVACAP.NS has a market cap of 38.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while INNOVACAP.NS trades at ₹691.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas INNOVACAP.NS's P/E ratio is 28.80. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check INNOVACAP.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SPARC.BO has a market cap of 35.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SPARC.BO trades at ₹111.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SPARC.BO's P/E ratio is -13.19. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SPARC.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SPARC.NS has a market cap of 35.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SPARC.NS trades at ₹111.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SPARC.NS's P/E ratio is -13.18. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SPARC.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SHILPAMED.BO has a market cap of 30.5B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SHILPAMED.BO trades at ₹338.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SHILPAMED.BO's P/E ratio is 27.63. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SHILPAMED.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, AARTIDRUGS.BO has a market cap of 29.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while AARTIDRUGS.BO trades at ₹335.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas AARTIDRUGS.BO's P/E ratio is 14.82. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AARTIDRUGS.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, AARTIDRUGS.NS has a market cap of 29.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while AARTIDRUGS.NS trades at ₹335.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas AARTIDRUGS.NS's P/E ratio is 14.82. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check AARTIDRUGS.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SUVEN.NS has a market cap of 29.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SUVEN.NS trades at ₹129.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SUVEN.NS's P/E ratio is -10.28. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUVEN.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SUVEN.BO has a market cap of 29.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SUVEN.BO trades at ₹129.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SUVEN.BO's P/E ratio is -10.29. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SUVEN.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, RPGLIFE.NS has a market cap of 28.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while RPGLIFE.NS trades at ₹1,781.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas RPGLIFE.NS's P/E ratio is 14.23. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check RPGLIFE.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, RPGLIFE.BO has a market cap of 28.7B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while RPGLIFE.BO trades at ₹1,763.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas RPGLIFE.BO's P/E ratio is 14.15. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check RPGLIFE.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, GUFICBIO.NS has a market cap of 28.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while GUFICBIO.NS trades at ₹278.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas GUFICBIO.NS's P/E ratio is 56.63. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GUFICBIO.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, GUFICBIO.BO has a market cap of 28.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while GUFICBIO.BO trades at ₹281.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas GUFICBIO.BO's P/E ratio is 56.43. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GUFICBIO.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, GUJTHEM.NS has a market cap of 28.1B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while GUJTHEM.NS trades at ₹264.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas GUJTHEM.NS's P/E ratio is 58.70. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check GUJTHEM.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ORCHPHARMA.BO has a market cap of 25.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ORCHPHARMA.BO trades at ₹513.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ORCHPHARMA.BO's P/E ratio is 136.27. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ORCHPHARMA.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ORCHPHARMA.NS has a market cap of 25.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ORCHPHARMA.NS trades at ₹511.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ORCHPHARMA.NS's P/E ratio is 134.85. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ORCHPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ORCHPHARMA.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, NOVARTIND.BO has a market cap of 22.8B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while NOVARTIND.BO trades at ₹915.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas NOVARTIND.BO's P/E ratio is 23.43. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check NOVARTIND.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, UNICHEMLAB.BO has a market cap of 21.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while UNICHEMLAB.BO trades at ₹299.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas UNICHEMLAB.BO's P/E ratio is 7.20. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check UNICHEMLAB.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, UNICHEMLAB.NS has a market cap of 21.2B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while UNICHEMLAB.NS trades at ₹297.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas UNICHEMLAB.NS's P/E ratio is 7.19. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check UNICHEMLAB.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, IOLCP.BO has a market cap of 21B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while IOLCP.BO trades at ₹77.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas IOLCP.BO's P/E ratio is 18.13. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check IOLCP.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, IOLCP.NS has a market cap of 21B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while IOLCP.NS trades at ₹77.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas IOLCP.NS's P/E ratio is 18.12. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check IOLCP.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SOLARA.BO has a market cap of 20.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SOLARA.BO trades at ₹443.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SOLARA.BO's P/E ratio is -90.58. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SOLARA.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, SOLARA.NS has a market cap of 20.9B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while SOLARA.NS trades at ₹440.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas SOLARA.NS's P/E ratio is -90.10. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check SOLARA.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, BLISSGVS.BO has a market cap of 20.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while BLISSGVS.BO trades at ₹206.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas BLISSGVS.BO's P/E ratio is 19.13. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check BLISSGVS.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, BLISSGVS.NS has a market cap of 20.6B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while BLISSGVS.NS trades at ₹206.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas BLISSGVS.NS's P/E ratio is 19.10. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check BLISSGVS.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, MOREPENLAB.NS has a market cap of 19.4B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while MOREPENLAB.NS trades at ₹36.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas MOREPENLAB.NS's P/E ratio is 19.63. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check MOREPENLAB.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, ALEMBICLTD.NS has a market cap of 19.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while ALEMBICLTD.NS trades at ₹76.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas ALEMBICLTD.NS's P/E ratio is 6.07. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, AUROPHARMA.NS is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check ALEMBICLTD.NS's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, HIKAL.BO has a market cap of 19.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while HIKAL.BO trades at ₹161.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas HIKAL.BO's P/E ratio is 196.00. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check HIKAL.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, MOREPENLAB.BO has a market cap of 19.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while MOREPENLAB.BO trades at ₹36.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas MOREPENLAB.BO's P/E ratio is 19.71. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check MOREPENLAB.BO's competition here

AUROPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AUROPHARMA.NS stands at 742.7B. In comparison, HIKAL.NS has a market cap of 19.3B. Regarding current trading prices, AUROPHARMA.NS is priced at ₹1,281.60, while HIKAL.NS trades at ₹161.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AUROPHARMA.NS currently has a P/E ratio of 21.29, whereas HIKAL.NS's P/E ratio is -147.67. In terms of profitability, AUROPHARMA.NS's ROE is +0.11%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, AUROPHARMA.NS is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AUROPHARMA.NS.Check HIKAL.NS's competition here